Compound Profiles

Body Protection Compound-157

Synthetic peptide derived from human gastric juice. Extensive positive animal data for tendon, ligament and gut healing. No large-scale human trials.

GLP-1 Receptor Agonist

FDA-approved GLP-1 agonist with robust evidence for weight management, type 2 diabetes, and cardiovascular outcomes. Broad compounding effectively prohibited as of April 2026.

Dual GIP/GLP-1 Receptor Agonist

FDA-approved dual-action incretin mimetic. Superior weight loss vs semaglutide in head-to-head trial. Same compounding restrictions as semaglutide.

Melanocortin Receptor Agonist (Bremelanotide)

FDA-approved as Vyleesi for HSDD in premenopausal women. Acts on the central nervous system to increase sexual desire. Off-label use growing via compounding.

Growth Hormone Secretagogue Combination

Growth hormone secretagogue combination with synergistic effects. Documented human data for GH elevation. PCAC reviewed both compounds in late 2024 and did not recommend them for the 503A bulks list.

Thymosin Beta-4 (synthetic fragment)

Synthetic Thymosin Beta-4. Frequently combined with BPC-157 for tissue repair through complementary mechanisms. Strongest human data is in ophthalmic applications.

Tα1 / Zadaxin (Immune Modulator)

Approved as Zadaxin in 35+ countries for hepatitis B and C. One of the strongest international evidence profiles in the peptide space. PCAC reviewed Tα1 in December 2024 and did not recommend it for the 503A bulks list.

ACTH 4–10 Analog (Cognitive Nasal Peptide)

Russian-approved cognitive nasal peptide that modulates dopamine/serotonin and upregulates BDNF. The strongest evidence-to-risk ratio in the cognitive category, with the caveat that most research is in Russian.

Tuftsin Analog (Anxiolytic Nasal Peptide)

Nasal anxiolytic that modulates GABA without sedation, dependency, or tolerance. Referred to PCAC September 2024; remains Category 2 with no scheduled review. Frequently paired with Semax.

Delta Sleep-Inducing Peptide (Emideltide)

Sleep-architecture peptide first isolated in 1977. Named for delta-wave sleep promotion. Thinnest evidence base of any compound on the July 2026 PCAC agenda — decades-old research, no modern controlled trials.

AEDG Tetrapeptide (Pineal-Derived)

Synthetic pineal peptide studied for sleep/circadian effects and telomerase activation. 25+ years of research, mostly from a single Russian institute. Sleep effects are the most credible practitioner-reported outcome; longevity claims outpace controlled evidence.

Glycyl-L-Histidyl-L-Lysine Copper Peptide

Copper peptide with strong topical evidence for skin aging, scar reduction, and hair growth. Injectable systemic use has minimal clinical data. Second PCAC meeting before February 2027.

Mitochondrial-Derived Peptide

Mitochondrial-derived peptide that activates AMPK to improve insulin sensitivity and metabolic regulation. Sometimes called an ‘exercise mimetic.’ On the July 23, 2026 PCAC agenda.

Lysine-Proline-Valine (α-MSH tripeptide)

Tripeptide fragment of alpha-MSH studied for inflammatory bowel applications. Strongest mechanistic case of any compound on the July 2026 PCAC agenda. No large-scale human trials.

Synthetic Hexapeptide (HGF/c-Met activator)

The most hyped and least proven cognitive peptide. Foundational research has been retracted, no human trials exist, and the ‘millions of times more potent than BDNF’ claim traces back to compromised work. We cannot recommend it.

Spadin Analog (TREK-1 Channel Inhibitor)

Early-stage spadin analog targeting TREK-1 channels for mood and cognition. Almost entirely preclinical with minimal published data. Included for completeness.